The variants of SARS-CoV-2 circulating in France in autumn 2026, mainly XFG (known as “Stratus”) and PJ.2.1, raise a recurring question: do these strains cause truly new symptoms? The available data, particularly those relayed by Santé publique France and Vaccination Info Service, allow us to measure what has changed compared to previous waves, and especially what has not changed despite alarming headlines.
Covid Symptoms 2026 Compared to Previous Strains
The comparison between the clinical manifestations of the variants circulating in 2026 and those of the early Omicron strains reveals more continuity than disruption. The table below summarizes the signs reported in French and international medical sources.
| Symptom | Omicron Variants (2022-2024) | XFG / PJ.2.1 (autumn 2026) |
|---|---|---|
| Sore throat | Common | Common, often described as sharp |
| Nasopharyngeal congestion / runny nose | Common | Common, almost systematic |
| Cough | Common | Common |
| Fever / chills | Common | Common |
| Fatigue | Common | Common, sometimes prolonged |
| Headaches | Frequent | Frequent |
| Muscle pain | Frequent | Frequent |
| Hoarseness | Rarely reported | Mentioned with XFG, without formal evidence |
| Loss of taste / smell | Less frequent than with Delta | Still possible, frequency declining |
| Digestive issues | Less common | Still reported (nausea, diarrhea) |
The observation is clear: no symptom specific to the 2026 variants is scientifically established. The manifestations remain those of a dominant ENT syndrome, with a tropism for the upper respiratory tract rather than the lungs.
A detailed file on Covid 2026 on Compar Santé discusses this clinical evolution and the precautions to take in the face of current variants.
Hoarseness and Variant XFG: Weak Signal or True Clinical Marker
Among the signs fueling discussions, hoarseness occupies a special place. Several recent articles, notably relayed by Yahoo News, mention it in connection with the XFG variant. A hoarse or broken voice seems to appear more often than with previous strains.
The nuance is significant: no health authority has validated hoarseness as a diagnostic sign. An epidemiologist quoted by actu.fr reminds us that no new symptomatology is formally established for the XFG and PJ.2.1 variants that are predominant in France. Hoarseness can accompany any upper respiratory tract infection, including seasonal flu.
What makes this signal interesting is its recurrence in testimonies from patients who tested positive in autumn 2026. But anecdotal recurrence and clinical evidence are two distinct things. Only a test can confirm an infection with SARS-CoV-2, not the quality of the voice.
Loss of Smell in 2026: A Symptom in Decline but Still Present
Anosmia (loss of smell) and ageusia (loss of taste) have long been the most distinctive markers of Covid-19, particularly with pre-Omicron and Delta variants. In 2026, the situation has changed.
Vaccination Info Service indicates that loss of smell is less frequent with Omicron sub-variants, of which XFG is a part. It has not disappeared, however: some patients still report it, sometimes transiently over a few days.
This evolution has a direct practical consequence. Many people still associate “Covid” with “loss of smell.” The absence of this sign may lead them to dismiss the possibility of an infection and not get tested. However, the current clinical picture resembles more a severe cold or flu than the Covid we knew in 2020.
Digestive Issues and Confusion: Not New Symptoms
Nausea, vomiting, diarrhea, and abdominal pain have been among the less common signs of Covid-19 since the beginning of the pandemic. Vaccination Info Service still mentions them in its list of possible manifestations.
Mental confusion, sometimes mentioned in alarming articles, falls into the same category. It did not appear with the 2026 variants. Its isolated presence does not allow attributing the infection to a particular variant.
- Digestive issues occur in a minority of patients, regardless of the variant, and do not constitute a differentiating criterion
- Confusion remains a warning sign justifying a quick consultation, but it also accompanies other viral infections with high fever
- Shortness of breath, although less frequent than with historical strains, can still occur and requires immediate medical attention
Covid, Flu, or Cold in Autumn 2026: The Limits of Symptom-Based Diagnosis
The convergence of clinical pictures between Covid-19, seasonal flu, and rhinovirus infections complicates diagnosis based solely on symptoms. Santé publique France now includes SARS-CoV-2 in a global surveillance of acute respiratory infections, alongside flu and bronchiolitis.
This grouping reflects a clinical reality: symptoms no longer allow distinguishing Covid from flu without a test. Medical consultations are on the rise with the onset of autumn, and the virus is actively circulating in the majority of French departments.
Some useful pointers nonetheless:
- Sore throat tends to be more pronounced with the current Covid variants than with classic flu, where muscle pain often predominates
- Sudden fever and intense body aches lean more towards flu, while progressive nasal congestion with an irritated throat suggests Covid or a rhinovirus
The antigenic or PCR test remains the only reliable tool to make a decision. In periods of viral co-circulation, relying solely on symptoms exposes one to the risk of unintentional transmission, particularly to vulnerable individuals for whom vaccination and barrier measures remain recommended by the Ministry of Health.
The XFG and PJ.2.1 variants have not reinvented the disease. Covid-19 in 2026 resembles a flu-like syndrome centered on the throat and nose, with a notable decline in severe lung involvement. The absence of truly new symptoms does not mean the absence of risk: the confusion with other winter viruses makes testing all the more relevant.
